Ben Derman/X
Dec 19, 2024, 15:56
HBI0101 BCMA-directed CAR-T experience in AL amyloid, summarised by Ben Derman
Ben Derman, Assistant Professor at University of Chicago, shared an article by Eyal Lebel on X:
“Following up on presentation from ASCO, the HBI0101 BCMA-directed CAR T experience in AL amyloid.
- n=16, a very high-risk amyloid group (5 pts with stage III!) and heavily pre-treated
- Obviously lower disease burden in the marrow (range 0.3-15%)
- Heavy use of toci for CRS (sensible given population)
- 94% ORR, 75% CR rate, and 64% MRD<10^-5
- Median f/u 8.4 months
- EFS 9.6 mos. and OS 10.1 mos. Hindered by 7 deaths (4 after relapse).
- Applaud the enrollment of high-risk population; hard to comment on durability given early deaths. Seems like not for stage IIIA/B.
- h/t Rafael Fonseca re: mindmap image.
Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis.
Authors: Eyal Lebel, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 19, 2024, 15:19
Dec 19, 2024, 14:31
Dec 19, 2024, 14:28
Dec 19, 2024, 14:26
Dec 19, 2024, 14:11